Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats

Diabetes Research and Clinical Practice

Volumn 62, Issue 2, 2003, Pages 69-77

  Oya, M ^a   Hosokawa, M ^a   Tsukada, H ^a   Fukuda, K ^a   Nakamura, H ^a   Tsukiyama, K ^a   Nagashima, K ^a   Fujimoto, S ^a   Yamada, Y ^a   Seino, Y ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Aldose reductase inhibitor; Diabetes mellitus; Gastroenteropathy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; PARACETAMOL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHLORIDE TRANSPORT; COLON MUCOSA; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ELECTROSTIMULATION; GASTROINTESTINAL DISEASE; ION TRANSPORT; MALE; NONHUMAN; RAT; STOMACH EMPTYING; WATER TRANSPORT;

EID: 10744220449     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00165-7     Document Type: Article

References (33)

1. Horowitz M., Wishart J.M., Jones K.L., Hebbard G.S. Gastric emptying in diabetes: an overview. Diabetic Med. 13:1996;S16-S22.
2. Talley N.J., Young L., Bytzer P., et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am. J. Gastroenterol. 96:2001;71-76.
3. Camilleri M. Gastrointestinal problems in diabetes. Endocrinol. Metab. Clin. North Am. 25:1996;361-378.
4. Haines S.T. Treating constipation in the patient with diabetes. Diabetes Educ. 21:1995;223-232.
5. Beebe D.K., Walley E. Diabetic diarrhea. An underdiagnosed complication? Postgrad. Med. 91:1992;179-186.
6. Pfeifer M.A., Schumer M.P. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes. 44:1995;1355-1361.
7. Greene D. The pathogenesis and prevention of diabetic neuropathy and nephropathy. Metabolism. 37:1988;25-29.
8. Hotta N., Sakamoto N., Shigeta Y., Kikkawa R., Goto Y. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic neuropathy study group in Japan. J. Diabetes Complications. 10:1996;168-172.
9. Nakamura T., Okano R., Uchiyama H., Seo Y., Okuda S. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation. Intern. Med. 36:1997;479-483.
10. Liu H.S., Karakida T., Homma S. In vitro motor activity and compliance of the caecum in streptozotocin diabetic rats. Jpn. J. Physiol. 40:1990;843-851.
11. Perdue M.H., Davison J.S. Altered regulation of intestinal ion transport by enteric nerves in diabetic rats. Am. J. Physiol. 254:1988;G444-G449.
12. Nowak T.V., Harrington B., Kalbfleisch J.H., Amatruda J.M. Evidence for abnormal cholinergic neuromuscular transmission in diabetic rat small intestine. Gastroenterology. 91:1986;124-132.
13. Hatanaka S., Kondoh M., Kawarabayashi K., Furuhama K. The measurement of gastric emptying in conscious rats by monitoring serial changes in serum acetaminophen level. J. Pharmacol. Toxicol. Methods. 31:1994;161-165.
14. Hotta N., Kakuta H., Fukasawa H., et al. Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats. Diabetologia. 28:1985;176-180.
15. Sasaki H., Naka K., Kishi Y., et al. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats. Exp. Neurol. 146:1997;466-470.
16. Hosokawa M., Tsukada H., Ueda S., et al. Regulation of ion transport by endothelins in rat colonic mucosa: effects of an ETA antagonist (FR139317) and an ETB agonist (IRL1620). J. Pharmacol. Exp. Ther. 273:1995;1313-1322.
17. Perdue M.H., Davison J.S. Response of jejunal mucosa to electrical transmural stimulation and two neurotoxins. Am. J. Physiol. 251:1986;G642-648.
18. Poggioli R., Vitale G., Colombo G., Ottani A., Bertolini A. Gamma-hydroxybutyrate increases gastric emptying in rats. Life Sci. 64:1999;2149-2154.
19. Dharmsathaphorn K., Pandol S.J. Mechanism of chloride secretion induced by carbachol in a colonic epithelial cell line. J. Clin. Invest. 77:1986;348-354.
20. Enck P., Rathmann W., Spiekermann M., et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z. Gastroenterol. 32:1994;637-641.
21. Maxton D.G., Whorwell P.J. Functional bowel symptoms in diabetes - the role of autonomic neuropathy. Postgrad. Med. J. 67:1991;991-993.
22. Chang E.B., Fedorak R.N., Field M. Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. Gastroenterology. 91:1986;564-569.
23. Ogbonnaya K.I., Arem R. Diabetic diarrhea. Pathophysiology, diagnosis, and management. Arch. Intern. Med. 150:1990;262-267.
24. Roza A.M., Edmiston C.E., Frantzides C., et al. Untreated diabetes mellitus promotes intestinal microbial overgrowth. Am. J. Surg. 163:1992;417-421.
25. Falchuk K.R., Conlin D. The intestinal and liver complications of diabetes mellitus. Adv. Intern. Med. 38:1993;269-286.
26. Iber F.L., Parveen S., Vandrunen M., et al. Relation of symptoms to impaired stomach, small bowel, and colon motility in long-standing diabetes. Dig. Dis. Sci. 38:1993;45-50.
27. Kasai S., Tanaka K., Machimura H., et al. Effect of cisapride on gastric emptying in diabetic patients without gastrointestinal symptoms. Tokai J. Exp. Clin. Med. 16:1991;97-102.
28. Gullikson G.W., Virina M.A., Loeffler R.F., et al. SC-49518 enhances gastric emptying of solid and liquid meals and stimulates gastrointestinal motility in dogs by a 5-hydroxytryptamine4 receptor mechanism. J. Pharmacol. Exp. Ther. 264:1993;240-248.
29. Kikkawa R., Hatanaka I., Yasuda H., et al. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene] rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia. 24:1983;290-292.
30. Sima A.A., Bril V., Nathaniel V., et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. New Engl. J. Med. 319:1988;548-555.
31. Yoshida T., Nishioka H., Yoshioka K., et al. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Diabetes. 36:1987;6-13.
32. Nowak T.V., Harrington B., Kalbfleisch J.H., et al. Evidence for abnormal cholinergic neuromuscular transmission in diabetic rat small intestine. Gastroenterology. 91:1986;124-132.
33. Pfeifer M.A., Schumer M.P., Gelber D.A. Aldose reductase inhibitors: the end of an era or the need for different trial designs. Diabetes. 46:1997;S82-89.